Adding Thymosin Alpha-1 to Interferon Therapy Improves Hepatitis C Treatment Response | Research

The takeaway

Combining thymosin alpha-1 with interferon-alpha produced higher sustained response rates in hepatitis C patients compared to interferon alone.

17 vs 17 patients
Combination therapy with thymosin alpha-1 showed superior biochemical and virological response rates over interferon alone

What the researchers found

Thymosin alpha-1 (1 mg twice weekly) combined with interferon-alpha-2b (3 MU three times weekly) produced superior biochemical and virological responses compared to interferon alone in treatment-naive chronic hepatitis C patients.

Why it matters

Hepatitis C was a major global health burden in 1998. Finding that thymosin alpha-1 could enhance interferon therapy offered a way to improve cure rates for a disease that was difficult to treat at the time.

How the study worked

Randomized controlled trial comparing IFN-alpha-2b + thymosin alpha-1 (n=17) versus IFN-alpha-2b alone (n=17) in treatment-naive chronic hepatitis C patients. Assessed biochemical (ALT normalization) and virological (HCV RNA) response.

What this study cannot tell us

Small sample size (17 per group). Preliminary results without long-term follow-up. The hepatitis C treatment landscape has changed dramatically since this study.

How to read the evidence

Moderate evidence from a small randomized trial. Clear methodology but limited by sample size and preliminary nature of results.

When this study was published

Published in 1998. Hepatitis C treatment has been revolutionized by direct-acting antivirals, making interferon-based regimens largely obsolete. However, thymosin alpha-1's immune-boosting principle remains relevant.

The bigger picture

While direct-acting antivirals have since revolutionized hepatitis C treatment, this study demonstrated thymosin alpha-1's ability to boost antiviral immune responses — a principle that remains relevant for other viral infections where immune enhancement could improve treatment outcomes.

Questions still open

Does thymosin alpha-1 enhance antiviral immunity through T-cell activation specifically?
Could thymosin alpha-1 boost treatment response for other viral infections?
What is the optimal dose of thymosin alpha-1 for immune enhancement?

Common questions

What is thymosin alpha-1?

Thymosin alpha-1 is a peptide naturally produced by the thymus gland that enhances immune system function, particularly T-cell activity. It has been studied as an adjunct therapy for viral infections and cancer.

Is this treatment still used for hepatitis C?

No. Hepatitis C is now treated with direct-acting antiviral drugs that cure over 95% of patients. However, thymosin alpha-1's ability to boost antiviral immunity remains of interest for other conditions.

Read the original research

Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.

Liver, 18(5), 366-9

View on PubMed ↗

Citation

Moscarella, S; Buzzelli, G; Romanelli, R G; Monti, M; Giannini, C; Careccia, G; Marrocchi, E M; Zignego, A L. (1998). Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.. Liver, 18(5), 366-9.